guest ::
| Home > Publications database > Salt-inducible kinase 3 protects tumor cells from cytotoxic T-cell attack by promoting TNF-induced NF-κB activation. > print |
| Home > Publications database > Salt-inducible kinase 3 protects tumor cells from cytotoxic T-cell attack by promoting TNF-induced NF-κB activation. > print |
| 001 | 180022 | ||
| 005 | 20240229145602.0 | ||
| 024 | 7 | _ | |a 10.1136/jitc-2021-004258 |2 doi |
| 024 | 7 | _ | |a pmid:35606086 |2 pmid |
| 024 | 7 | _ | |a altmetric:128783127 |2 altmetric |
| 037 | _ | _ | |a DKFZ-2022-01039 |
| 041 | _ | _ | |a English |
| 082 | _ | _ | |a 610 |
| 100 | 1 | _ | |a Sorrentino, Antonio |0 P:(DE-He78)3b7da5ed0bbbfa153e8bdf23d212ae8c |b 0 |e First author |
| 245 | _ | _ | |a Salt-inducible kinase 3 protects tumor cells from cytotoxic T-cell attack by promoting TNF-induced NF-κB activation. |
| 260 | _ | _ | |a London |c 2022 |b BioMed Central |
| 336 | 7 | _ | |a article |2 DRIVER |
| 336 | 7 | _ | |a Output Types/Journal article |2 DataCite |
| 336 | 7 | _ | |a Journal Article |b journal |m journal |0 PUB:(DE-HGF)16 |s 1678886351_29495 |2 PUB:(DE-HGF) |
| 336 | 7 | _ | |a ARTICLE |2 BibTeX |
| 336 | 7 | _ | |a JOURNAL_ARTICLE |2 ORCID |
| 336 | 7 | _ | |a Journal Article |0 0 |2 EndNote |
| 500 | _ | _ | |a #EA:D015# |
| 520 | _ | _ | |a Cancer immunotherapeutic strategies showed unprecedented results in the clinic. However, many patients do not respond to immuno-oncological treatments due to the occurrence of a plethora of immunological obstacles, including tumor intrinsic mechanisms of resistance to cytotoxic T-cell (TC) attack. Thus, a deeper understanding of these mechanisms is needed to develop successful immunotherapies.To identify novel genes that protect tumor cells from effective TC-mediated cytotoxicity, we performed a genetic screening in pancreatic cancer cells challenged with tumor-infiltrating lymphocytes and antigen-specific TCs.The screening revealed 108 potential genes that protected tumor cells from TC attack. Among them, salt-inducible kinase 3 (SIK3) was one of the strongest hits identified in the screening. Both genetic and pharmacological inhibitions of SIK3 in tumor cells dramatically increased TC-mediated cytotoxicity in several in vitro coculture models, using different sources of tumor and TCs. Consistently, adoptive TC transfer of TILs led to tumor growth inhibition of SIK3-depleted cancer cells in vivo. Mechanistic analysis revealed that SIK3 rendered tumor cells susceptible to tumor necrosis factor (TNF) secreted by tumor-activated TCs. SIK3 promoted nuclear factor kappa B (NF-κB) nuclear translocation and inhibited caspase-8 and caspase-9 after TNF stimulation. Chromatin accessibility and transcriptome analyses showed that SIK3 knockdown profoundly impaired the expression of prosurvival genes under the TNF-NF-κB axis. TNF stimulation led to SIK3-dependent phosphorylation of the NF-κB upstream regulators inhibitory-κB kinase and NF-kappa-B inhibitor alpha on the one side, and to inhibition of histone deacetylase 4 on the other side, thus sustaining NF-κB activation and nuclear stabilization. A SIK3-dependent gene signature of TNF-mediated NF-κB activation was found in a majority of pancreatic cancers where it correlated with increased cytotoxic TC activity and poor prognosis.Our data reveal an abundant molecular mechanism that protects tumor cells from cytotoxic TC attack and demonstrate that pharmacological inhibition of this pathway is feasible. |
| 536 | _ | _ | |a 314 - Immunologie und Krebs (POF4-314) |0 G:(DE-HGF)POF4-314 |c POF4-314 |f POF IV |x 0 |
| 588 | _ | _ | |a Dataset connected to CrossRef, PubMed, , Journals: inrepo02.dkfz.de |
| 650 | _ | 7 | |a CD8-positive T-lymphocytes |2 Other |
| 650 | _ | 7 | |a cytokines |2 Other |
| 650 | _ | 7 | |a immunomodulation |2 Other |
| 650 | _ | 7 | |a immunotherapy |2 Other |
| 650 | _ | 7 | |a tumor escape |2 Other |
| 700 | 1 | _ | |a Menevse, Ayse Nur |b 1 |
| 700 | 1 | _ | |a Michels, Tillmann |0 P:(DE-He78)9ddf8548567817f5761b4db4cca412d3 |b 2 |
| 700 | 1 | _ | |a Volpin, Valentina |0 P:(DE-He78)b047f9932dd30887b942fa53c39d415e |b 3 |
| 700 | 1 | _ | |a Durst, Franziska Christine |0 0000-0001-6714-0321 |b 4 |
| 700 | 1 | _ | |a Sax, Julian |b 5 |
| 700 | 1 | _ | |a Xydia, Maria |b 6 |
| 700 | 1 | _ | |a Hussein, Abir |b 7 |
| 700 | 1 | _ | |a Stamova, Slava |b 8 |
| 700 | 1 | _ | |a Spoerl, Steffen |b 9 |
| 700 | 1 | _ | |a Heuschneider, Nicole |b 10 |
| 700 | 1 | _ | |a Muehlbauer, Jasmin |b 11 |
| 700 | 1 | _ | |a Jeltsch, Katharina Marlene |b 12 |
| 700 | 1 | _ | |a Rathinasamy, Anchana |b 13 |
| 700 | 1 | _ | |a Werner-Klein, Melanie |b 14 |
| 700 | 1 | _ | |a Breinig, Marco |0 P:(DE-He78)a7f6241ee41dbfd09892f8027db893d0 |b 15 |u dkfz |
| 700 | 1 | _ | |a Mikietyn, Damian |b 16 |
| 700 | 1 | _ | |a Kohler, Christian |b 17 |
| 700 | 1 | _ | |a Poschke, Isabel |0 P:(DE-He78)e9c55f46b4b06cf835834ee7e3e00db8 |b 18 |u dkfz |
| 700 | 1 | _ | |a Purr, Sabrina |0 P:(DE-HGF)0 |b 19 |
| 700 | 1 | _ | |a Reidell, Olivia |b 20 |
| 700 | 1 | _ | |a Martins Freire, Catarina |b 21 |
| 700 | 1 | _ | |a Offringa, Rienk |0 P:(DE-He78)81ae96953d6149e4307057d71a190019 |b 22 |u dkfz |
| 700 | 1 | _ | |a Gebhard, Claudia |b 23 |
| 700 | 1 | _ | |a Spang, Rainer |b 24 |
| 700 | 1 | _ | |a Rehli, Michael |b 25 |
| 700 | 1 | _ | |a Boutros, Michael |0 P:(DE-He78)3c0da8e3caa2aa50cad85152aa0465ad |b 26 |u dkfz |
| 700 | 1 | _ | |a Schmidl, Christian |b 27 |
| 700 | 1 | _ | |a Khandelwal, Nisit |0 P:(DE-He78)28a758c72be594bcb254fe9f3ac6be04 |b 28 |
| 700 | 1 | _ | |a Beckhove, Philipp |0 P:(DE-He78)1732377f6242a18280bc6aaa196988d1 |b 29 |e Last author |
| 773 | _ | _ | |a 10.1136/jitc-2021-004258 |g Vol. 10, no. 5, p. e004258 - |0 PERI:(DE-600)2719863-7 |n 5 |p e004258 |t Journal for ImmunoTherapy of Cancer |v 10 |y 2022 |x 2051-1426 |
| 909 | C | O | |p VDB |o oai:inrepo02.dkfz.de:180022 |
| 910 | 1 | _ | |a Deutsches Krebsforschungszentrum |0 I:(DE-588b)2036810-0 |k DKFZ |b 0 |6 P:(DE-He78)3b7da5ed0bbbfa153e8bdf23d212ae8c |
| 910 | 1 | _ | |a Deutsches Krebsforschungszentrum |0 I:(DE-588b)2036810-0 |k DKFZ |b 2 |6 P:(DE-He78)9ddf8548567817f5761b4db4cca412d3 |
| 910 | 1 | _ | |a Deutsches Krebsforschungszentrum |0 I:(DE-588b)2036810-0 |k DKFZ |b 3 |6 P:(DE-He78)b047f9932dd30887b942fa53c39d415e |
| 910 | 1 | _ | |a Deutsches Krebsforschungszentrum |0 I:(DE-588b)2036810-0 |k DKFZ |b 15 |6 P:(DE-He78)a7f6241ee41dbfd09892f8027db893d0 |
| 910 | 1 | _ | |a Deutsches Krebsforschungszentrum |0 I:(DE-588b)2036810-0 |k DKFZ |b 18 |6 P:(DE-He78)e9c55f46b4b06cf835834ee7e3e00db8 |
| 910 | 1 | _ | |a Deutsches Krebsforschungszentrum |0 I:(DE-588b)2036810-0 |k DKFZ |b 19 |6 P:(DE-HGF)0 |
| 910 | 1 | _ | |a Deutsches Krebsforschungszentrum |0 I:(DE-588b)2036810-0 |k DKFZ |b 22 |6 P:(DE-He78)81ae96953d6149e4307057d71a190019 |
| 910 | 1 | _ | |a Deutsches Krebsforschungszentrum |0 I:(DE-588b)2036810-0 |k DKFZ |b 26 |6 P:(DE-He78)3c0da8e3caa2aa50cad85152aa0465ad |
| 910 | 1 | _ | |a Deutsches Krebsforschungszentrum |0 I:(DE-588b)2036810-0 |k DKFZ |b 28 |6 P:(DE-He78)28a758c72be594bcb254fe9f3ac6be04 |
| 910 | 1 | _ | |a Deutsches Krebsforschungszentrum |0 I:(DE-588b)2036810-0 |k DKFZ |b 29 |6 P:(DE-He78)1732377f6242a18280bc6aaa196988d1 |
| 913 | 1 | _ | |a DE-HGF |b Gesundheit |l Krebsforschung |1 G:(DE-HGF)POF4-310 |0 G:(DE-HGF)POF4-314 |3 G:(DE-HGF)POF4 |2 G:(DE-HGF)POF4-300 |4 G:(DE-HGF)POF |v Immunologie und Krebs |x 0 |
| 914 | 1 | _ | |y 2022 |
| 915 | _ | _ | |a Creative Commons Attribution-NonCommercial CC BY-NC (No Version) |0 LIC:(DE-HGF)CCBYNCNV |2 V:(DE-HGF) |b DOAJ |d 2021-01-28 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0160 |2 StatID |b Essential Science Indicators |d 2021-01-28 |
| 915 | _ | _ | |a WoS |0 StatID:(DE-HGF)0113 |2 StatID |b Science Citation Index Expanded |d 2021-01-28 |
| 915 | _ | _ | |a Article Processing Charges |0 StatID:(DE-HGF)0561 |2 StatID |d 2021-01-28 |
| 915 | _ | _ | |a Fees |0 StatID:(DE-HGF)0700 |2 StatID |d 2021-01-28 |
| 915 | _ | _ | |a JCR |0 StatID:(DE-HGF)0100 |2 StatID |b J IMMUNOTHER CANCER : 2021 |d 2022-11-08 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0200 |2 StatID |b SCOPUS |d 2022-11-08 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0300 |2 StatID |b Medline |d 2022-11-08 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0501 |2 StatID |b DOAJ Seal |d 2021-01-14T19:11:13Z |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0500 |2 StatID |b DOAJ |d 2021-01-14T19:11:13Z |
| 915 | _ | _ | |a Peer Review |0 StatID:(DE-HGF)0030 |2 StatID |b DOAJ : Blind peer review |d 2021-01-14T19:11:13Z |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0600 |2 StatID |b Ebsco Academic Search |d 2022-11-08 |
| 915 | _ | _ | |a Peer Review |0 StatID:(DE-HGF)0030 |2 StatID |b ASC |d 2022-11-08 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0199 |2 StatID |b Clarivate Analytics Master Journal List |d 2022-11-08 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0150 |2 StatID |b Web of Science Core Collection |d 2022-11-08 |
| 915 | _ | _ | |a IF >= 10 |0 StatID:(DE-HGF)9910 |2 StatID |b J IMMUNOTHER CANCER : 2021 |d 2022-11-08 |
| 920 | 1 | _ | |0 I:(DE-He78)D015-20160331 |k D015 |l Translationale Immunologie |x 0 |
| 920 | 1 | _ | |0 I:(DE-He78)F190-20160331 |k F190 |l F190 NWG Cell Plasticity and Epigenetic Remodeling |x 1 |
| 920 | 1 | _ | |0 I:(DE-He78)D200-20160331 |k D200 |l Molekulare Grundlagen Gastrointestinaler Tumoren |x 2 |
| 920 | 1 | _ | |0 I:(DE-He78)D170-20160331 |k D170 |l KKE Neuroimmunologie und Hirntumorimmunologie |x 3 |
| 920 | 1 | _ | |0 I:(DE-He78)HD01-20160331 |k HD01 |l DKTK HD zentral |x 4 |
| 920 | 0 | _ | |0 I:(DE-He78)D015-20160331 |k D015 |l Translationale Immunologie |x 0 |
| 980 | _ | _ | |a journal |
| 980 | _ | _ | |a VDB |
| 980 | _ | _ | |a I:(DE-He78)D015-20160331 |
| 980 | _ | _ | |a I:(DE-He78)F190-20160331 |
| 980 | _ | _ | |a I:(DE-He78)D200-20160331 |
| 980 | _ | _ | |a I:(DE-He78)D170-20160331 |
| 980 | _ | _ | |a I:(DE-He78)HD01-20160331 |
| 980 | _ | _ | |a UNRESTRICTED |
| Library | Collection | CLSMajor | CLSMinor | Language | Author |
|---|